Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nektar Therapeutics granted non-qualified stock options to purchase an aggregate of 36,000 shares to 23 newly-hired employees under its 2025 Inducement Plan on July 20. The options have an exercise price of $64.84 per share, equal to the closing price on the grant date, and vest over four years.
Key figures
- Exercise price
- 64.84
- Options granted
- 36000
- Vesting term years
- 8
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.